Immune parameters and outcomes during Ebola virus disease

JCI Insight

Volumn 4, Issue 1, 2019, Pages

  Reynard, Stéphanie ^a   Journeaux, Alexandra ^a   Gloaguen, Emilie ^b   Schaeffer, Justine ^a   Varet, Hugo ^c   Pietrosemoli, Natalia ^c   Mateo, Mathieu ^a   Baillet, Nicolas ^a   Laouenan, Cédric ^b,d   Raoul, Hervé ^e   Mullaert, Jimmy ^b   Baize, Sylvain ^a,c  

^a CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c INSTITUT PASTEUR   (France)

^d BICHAT HOSPITAL   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CHEMOKINE; CHITINASE 3 LIKE PROTEIN 1; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; EOTAXIN; FAS LIGAND; GRANZYME B; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE STORM; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; GUINEAN; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; LEUKOCYTE; MAGNETIC BEAD ASSAY; MALE; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TRANSCRIPTOMICS; VIRUS ISOLATION;

EID: 85070661201     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.125106     Document Type: Article

References (59)

1. Vernet MA, et al. Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight. 2017;2(6):e88864.
2. Hunt L, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15(11):1292–1299.
3. Cournac JM, et al. Rhabdomyolysis in Ebola Virus Disease. Results of an Observational Study in a Treatment Center in Guinea. Clin Infect Dis. 2016;62(1):19–23.
4. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S364–S371.
5. Schieffelin JS, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092–2100.
6. Baize S, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5(4):423–426.
7. Baize S, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 2002;128(1):163–168.
8. Villinger F, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999;179 Suppl 1:S188–S191.
9. Sanchez A, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol. 2004;78(19):10370–10377.
10. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J Pathol. 1978;125(3):131–138.
11. Geisbert TW, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol. 2003;163(6):2347–2370.
12. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d’Ivoire: clinical and biologic presentation. J Infect Dis. 1999;179 Suppl 1:S48–S53.
13. Bosio CM, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 2003;188(11):1630–1638.
14. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170(6):2797–2801.
15. Olejnik J, et al. Ebolaviruses associated with differential pathogenicity induce distinct host responses in human macrophages. J Virol. 2017;91(11):e00179-17.
16. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4(10):e837.
17. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80(2):171–186.
18. Ebihara H, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis. 2011;204 Suppl 3:S991–S999.
19. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis. 2000;5(1):5–7.
20. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol. 2004;17(3):390–400.
21. Leroy EM, Becquart P, Wauquier N, Baize S. Evidence for Ebola virus superantigen activity. J Virol. 2011;85(8):4041–4042.
22. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol. 2001;124(3):453–460.
23. Ruibal P, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533(7601):100–104.
24. Bah EI, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372(1):40–47.
25. Kerber R, et al. Kinetics of soluble mediators of the host response in Ebola virus disease. J Infect Dis. 2018;218(suppl_5):S496–S503.
26. Yuan X, Peng X, Li Y, Li M. Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm. 2015;2015:807976.
27. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res. 1997;16(1):59–70.
28. Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute athero-ma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96(2):396–399.
29. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–862.
30. McElroy AK, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210(4):558–566.
31. Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196 Suppl 2:S357–S363.
32. Schnittler HJ, Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis. 1998;27(2):404–406.
33. Geisbert TW, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163(6):2371–2382.
34. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol. 1995;146(6):1287–1301.
35. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis. 1999;179 Suppl 1:S199–S202.
36. Brown KA, Brown GA, Lewis SM, Beale R, Treacher DF. Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit? Int Immunopharmacol. 2016;36:291–299.
37. Bozza FA, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49.
38. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188(11):1613–1617.
39. Guignant C, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011;15(2):R99.
40. Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20(1):124.
41. Hattori N, et al. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock. 2009;32(4):393–400.
42. Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog. 2014;10(11):e1004509.
43. Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD, Diener KR. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 2017;7(1):5850.
44. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol, Cell Physiol. 2006;291(6):C1318–C1325.
45. Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A. The Toll-like receptor 4 antagonist eritoran protects mice from lethal filovirus challenge. MBio. 2017;8(2):e00226-17.
46. Iampietro M, Santos RI, Lubaki NM, Bukreyev A. Ebola virus shed glycoprotein triggers differentiation, infection, and death of monocytes through Toll-like receptor 4 activation. J Infect Dis. 2018;218(suppl_5):S327–S334.
47. Chan JK, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122(8):2711–2719.
48. Vourc’h M, Roquilly A, Asehnoune K. Trauma-induced damage-associated molecular patterns-mediated remote organ injury and immunosuppression in the acutely ill patient. Front Immunol. 2018;9:1330.
49. Wong G, et al. Pathogenicity comparison between the Kikwit and Makona Ebola virus variants in rhesus macaques. J Infect Dis. 2016;214(suppl 3):S281–S289.
50. Cárdenas WB, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol. 2006;80(11):5168–5178.
51. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015;13(11):663–676.
52. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138–150.
53. Taeb AM, Hooper MH, Marik PE. Sepsis: current definition, pathophysiology, diagnosis, and management. Nutr Clin Pract. 2017;32(3):296–308.
54. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatis-tics. 2003;4(2):249–264.
55. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
56. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012;40(17):e133.
57. Yang Y, Zou H. A fast unified algorithm for solving group-lasso penalize learning problems. Stat Comput. 2015;25(6):1129–1141. https://doi.org/10.1007/s11222-014-9498-5.
58. Yuan M, Lin Y. Model selection estimation in regression with grouped variables. JR Stat Soc Ser B (Statistical Methodol). 68(1):49–67. doi:10.1111/j.1467-9868.2005.00532.x.
59. Sachs MC. plotROC: A Tool for Plotting ROC Curves. J Stat Software. 2017;79(Code Snippet 2):1–19. doi:10.18637/jss.v079.c02.